Interstitial lung irAEs, such as pneumonitis, happen in approximately 10% of patients taking combination therapy compared to3% in PD-1/CTLA-4 monotherapy, and therefore, need particular attention from a physician to examine respiratory symptoms [144]. This evidence concerns the gene CTLA4 and pneumonitis.